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Mutations in fibroblast growth factor receptors (Fgfrs) 1–3 cause skeletal disease syndromes in humans. Although these Fgfrs are expressed at
various stages of chondrocyte and osteoblast development, their function in specific skeletal cell types is poorly understood. Using conditional
inactivation of Fgfr1 in osteo-chondrocyte progenitor cells and in differentiated osteoblasts, we provide evidence that FGFR1 signaling is
important for different stages of osteoblast maturation. Examination of osteogenic markers showed that inactivation of FGFR1 in osteo-chondro-
progenitor cells delayed osteoblast differentiation, but that inactivation of FGFR1 in differentiated osteoblasts accelerated differentiation. In vitro
osteoblast cultures recapitulated the in vivo effect of FGFR1 on stage-specific osteoblast maturation. In immature osteoblasts, FGFR1 deficiency
increased proliferation and delayed differentiation and matrix mineralization, whereas in differentiated osteoblasts, FGFR1 deficiency enhanced
mineralization. Furthermore, FGFR1 deficiency in differentiated osteoblasts resulted in increased expression of Fgfr3, a molecule that regulates
the activity of differentiated osteoblasts. Mice lacking Fgfr1, either in progenitor cells or in differentiated osteoblasts, showed increased bone mass
as adults. These data demonstrate that signaling through FGFR1 in osteoblasts is necessary to maintain the balance between bone formation and
remodeling through a direct effect on osteoblast maturation.
© 2006 Elsevier Inc. All rights reserved.Keywords: Fibroblast growth factor receptor 1 (FGFR1); Skeletal development; Chondrocyte; OsteoblastsIntroduction
Mutations in FGFRs account for many of the craniosynos-
tosis and chondrodysplasia syndromes in humans (Chen and
Deng, 2005; Morriss-Kay and Wilkie, 2005; Ornitz, 2005;
Ornitz and Marie, 2002). Although the vast majority of
mutations that cause craniosynostosis syndromes are associ-
ated with FGFR2, a single missense mutation in FGFR1
(P252R) can cause Pfeiffer syndrome and phenocopies several
Pfeiffer syndrome mutations in FGFR2 (Schell et al., 1995).
The same mutation has also been identified in a single patient
who presented with Jackson–Weiss syndrome (Roscioli et al.,
2000), a mild craniofacial syndrome. Other missense muta-
tions in FGFR1 cause osteoglophonic dysplasia, a syndrome⁎ Corresponding author.
E-mail address: dornitz@wustl.edu (D.M. Ornitz).
0012-1606/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2006.05.031involving craniosynostosis, rhizomelic dwarfism and non-
ossifying bone lesions (White et al., 2005). This genetic
evidence establishes a role for FGFR1 in skeletal development
and suggests that FGFR1, FGFR2 and FGFR3 signaling
pathways may have similar or redundant functions. In addition
to premature fusion of cranial sutures, several of the classic
craniosynostosis syndromes have associated phenotypes that
affect long bone development in the appendicular skeleton.
For example, Pfeiffer syndrome patients have characteristic
broad thumbs and toes, and Apert syndrome patients have soft
tissue and bony syndactyly (Wilkie et al., 2002). This suggests
that FGFR1 and FGFR2 are important for early limb
patterning and endochondral and intramembranous skeletal
development.
Fgfrs 1–3 are expressed in the developing and mature
skeleton in patterns suggestive of both unique and redundant
function (Ornitz and Marie, 2002). In the developing growth
plate, both Fgfr1 and Fgfr2 are expressed in condensing
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expressed in reserve chondrocytes and appears to be down
regulated in proliferating chondrocytes, whereas Fgfr1 is
expressed in hypertrophic chondrocytes. Later in develop-
ment, Fgfr1 and Fgfr2 are both expressed in the perichon-
drium and periosteum, tissues that give rise to osteoblasts and
cortical bone. In contrast to Fgfr1 and Fgfr2, Fgfr3 is
prominently expressed in proliferating chondrocytes where it
regulates cell growth and differentiation (Naski et al., 1998)
and in differentiated osteoblasts where it regulates bone
density and cortical thickness (Valverde-Franco et al., 2004;
Xiao et al., 2004).
Activating mutations in FGFR3 in humans and mice causes
achondroplasia, whereas mice lacking Fgfr3 (Fgfr3−/−) showed
skeletal overgrowth accompanied by increased chondrocyte
proliferation and an expanded proliferating and hypertrophic
chondrocyte zone (Chen et al., 1999; Colvin et al., 1996; Deng
et al., 1996; Naski et al., 1998). The skeletal overgrowth is
thought to result from failure of the growth plate to fully close.
As adults, Fgfr3−/− mice were osteopenic, suggesting a role for
FGFR3 signaling in differentiated, Fgfr3-expressing osteoblasts
(Valverde-Franco et al., 2004).
Mice lacking Fgfr2 (Fgfr2−/−) die at embryonic day 10.5
(E10.5), prior to skeletal development (Xu et al., 1998). The
contribution of FGFR2 signaling to skeletal development has
been clarified to some extent by using splice form-specific
knockouts and conditional gene deletion approaches in mice.
These studies demonstrated that FGFR2 positively regulates
bone growth and the anabolic function of osteoblasts. The
resulting phenotype of mice lacking mesenchymal Fgfr2
included skeletal dwarfism, decreased bone density, incomplete
formation of the dorsal vertebrae and tarsal joint fusion
(Eswarakumar et al., 2002; Yu et al., 2003).
Embryos lacking Fgfr1 (Fgfr1−/−) die shortly after gastru-
lation (Yamaguchi et al., 1994), necessitating a conditional
knockout approach to address function later in development.
Although the contribution of Fgfr1 to specific skeletal lineages
is not known, Fgfr1 has recently been shown to be important for
early limb bud development and distal skeletal patterning. Fgfr1
is expressed in limb bud mesenchyme that gives rise to
mesenchymal condensations and eventually to the chondro-
genic and osteogenic lineage (Orr-Urtreger et al., 1991; Peters
et al., 1992; Xu et al., 1999b). Hypomorphic alleles of Fgfr1 or
conditional inactivation of Fgfr1 prior to limb bud initiation
affects digital patterning and the formation of some skeletal
elements (Li et al., 2005; Partanen et al., 1998; Verheyden et
al., 2005). To address the role of FGFR1 signaling
specifically in the osteo-chondrocyte lineage, we have
conditionally inactivated Fgfr1 in osteo-chondro-progenitor
cells and in differentiated osteoblasts. Here we provide in
vivo and in vitro evidence that demonstrates multiple roles for
FGFR1 signaling in endochondral bone growth and remodel-
ing. We demonstrate that loss of signaling through FGFR1
results in a delay in terminal maturation of hypertrophic
chondrocytes. In osteoblasts, we show that FGFR1 signaling
differentially regulates osteoblast growth and differentiation
depending on the stage of osteoblast maturation.Materials and methods
Mice
The conditional allele for FGFR1 has been previously generated and
characterized (Pirvola et al., 2002). A null allele for FGFR1 (Fgfr1Δ/+) was
made by germline Cre-mediated excision of the floxed region of Fgfr1. Col2-
Cre transgenic mice (Ovchinnikov et al., 2000) were used to inactivate Fgfr1 in
the osteo-chondrocyte lineage. Mice heterozygous for an Fgfr1 null allele
(Fgfr1Δ/+) and heterozygous for Cre (Col2-Cre/+) were mated to mice
homozygous for a floxed allele of Fgfr1 (Fgfr1flox/flox). Conditional knockout
mice (Fgfr1Col2-cko) with a genotype Fgfr1flox/Δ,Col2-Cre/+, were born with a
normal Mendelian frequency. To selectively inactivate the floxed allele of Fgfr1
in differentiated osteoblasts, α1(I)-collagen-Cre (Col1-Cre) transgenic mice
(Dacquin et al., 2002) were mated to either Fgfr1flox/flox or Fgfr1flox/Δ mice to
yield Fgfr1Col1-cko conditional knockout mice. Both genotype combinations
were used for different experiments and both yielded similar phenotypes.
Osteoblast and osteoclast cell culture
Osteoblasts were derived from long bones following a protocol similar to
that used by Declercq et al. (2004). Briefly, femur and tibia from 1.5- to
3-month-old mice were separated from soft tissue, bone marrow was flushed out
with PBS, and bones were washed several times in PBS. Bone chips were then
incubated in α-minimal essential medium (α-MEM) containing 0.2 mg/ml
bacterial collagenase (type 1, Sigma) for 30 min at 37°C with shaking. The
medium was discarded and replaced with fresh medium containing collagenase
and incubated for an additional 30 min. Released cells were collected after three
collagenase digestions. Cells and digested bone pieces were collected by
centrifugation and suspended in α-MEM containing 10% fetal bovine serum and
antibiotics. Cells were then seeded onto 250 ml tissue culture flasks or 10 cm
plates and allowed to proliferate to confluence. To measure cell proliferation,
cells were trypsinized and 5000 cells were plated per well in a 96-well plate;
medium was replaced with medium containing 3H-thymidine (1 μCi/well) for
4 h before lysis and harvest on glass fiber filters. Mineralization medium
contained 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate.
Alkaline phosphatase activity in osteoblasts
Alkaline phosphatase enzymatic activity was measured using a colorimetric
assay (Sigma FAST™-pNitrophenyl Phosphate tablets, N9389, Sigma) as
described (Sugiyama et al., 2003). 10,000 cells per well were plated in a 24-well
plate.
Alizarin red staining of mineralized osteoblast cultures
Cell cultures were washed with PBS and then fixed in 70% ethanol for 1 h.
After fixation, cells were washed with water and stained with 0.4% Alizarin red
(Sigma) for 15 min. Cells were then washed with water, dehydrated with 70%
ethanol and dried. Quantification of mineral content was performed as described
(Murshed et al., 2005). Bound dye was dissolved in 10% glacial acetic acid and
measured at 405 nm.
β-Galactosidase staining
β-Galactosidase staining was performed as previously described (Yu et al.,
2003) on whole embryos or frozen sections.
In situ hybridization
Plasmids used to generate riboprobes for in situ hybridization were from the
following sources: Ihh (A. McMahon); Pth1r and Opn (H. Kronenberg);
Collagen X (B. Olson); Cbfa1/Runx2 (B. de Crombrugghe), Mmp9 (Z. Werb),
Trap (Ek-Rylander et al., 1991), Collagen I (Metsaranta et al., 1991), Fgfr1
(Peters et al., 1992). Radioactive in situ hybridization was performed on paraffin
embedded tissue as previously described (Xu et al., 1999a).
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The following antibodies were used for immunostaining: FGFR1 (1:400,
Santa Cruz), β-catenin (1:100, Santa Cruz), osteopontin (1:100, MPIIIB10,
Department of Biological Sciences, University of Iowa, Iowa City). The
secondary antibodies used in immunofluorescence staining were mouse anti
rabbit (1:100, Chemicon), goat anti mouse (1:200, Chemicon).
Bone morphometric analysis
Bone volume was estimated by tracing diaphyseal or trabecular bone areas
on photographed histological sections using Canvas X software. Cell numbers
were counted within a box drawn over comparable trabecular regions of control
and conditional knockout embryos.
RNA isolation, cDNA synthesis and qRT-PCR analysis
RNAwas isolated from three biological samples. Each sample consisted of
one 250-ml tissue culture flask of long-bone-derived cells grown in
mineralization media for 1–3 weeks. Total RNAwas isolated from cell cultures
or tissues using the RNAqueous™ kit (Ambion Inc.). Equal amounts of RNA
were used to prepare cDNAwith random hexamers and PCR amplification using
the manufacturer's protocol (Invitrogen SuperScript™). qRT-PCR amplifica-
tions used the following set of primers:
Gapdh: F-5′-TGGCAAAGTGGAGATTGTTGCC-3′;
R-5′-AAGATGGTGATGGGCTTCCCG-3′;
mFgfr1IIIc: F-5′CACATCGAGGTGAACGGGAGTAAG-3′; and
R-5′ CGCATCCTCAAAGGAGACATTCC-3′.
Fgfr2, Fgfr3 and ColI primers were as described (Chikazu et al., 2000;
Mathy et al., 2003; Saghizadeh et al., 2005). QRT-PCR analysis was performed
using SYBR green (BioRad) and a BioRad iCycler. Standard PCR amplification
conditions were as follows: Gadph: (30 cycles, 94°C for 1 min, 55°C for 1 min,
72°C for 1.50 min). RT-PCR primers to detect the Fgfr1 delta allele (Δ) were as
described (Ohkubo et al., 2004).
Bone mass measurements by dual energy x-ray absorptiometry
Bone mineral density (BMD) was measured using dual-energy X-ray
absorptiometry (DEXA) on whole mice not including the head, and analyzed on
a PIXImus mouse densitometer (LUNAR Corp., Madison, Wisconsin).Results
Expression of Fgfr1 in developing bone
In developing long bones, Fgfr1 is expressed in hypertrophic
chondrocytes, in the perichondrium and in the trabecular region
(primary spongiosa). To identify the specific cell types that
express FGFR1, histology and immunohistochemistry were
used to identify both cuboidal and spindle-shaped osteoblasts
and corresponding FGFR1-expressing cells. Cuboidal osteo-
blasts are large differentiated cells that produce an extracellular
matrix, and spindle-shaped osteoblasts are thin quiescent cells
that line bone trabeculae (Hoshi et al., 1999; Zhang et al., 2003).
At postnatal day 0 (P0), the trabecular region contained both
large cuboidal cells and spindle-shaped cells (Figs. 1A–C).
Similar to what was shown previously (Calvi et al., 2003; Glass
et al., 2005; Mansukhani et al., 2005; Zhang et al., 2003), both
of these populations of cells express osteopontin and β-catenin
(Figs. 1D–E′). Immunohistochemistry, with an antibody againstthe carboxy terminus of FGFR1, showed FGFR1 expression in
a similar pattern to these osteoblast markers in both cuboidal
and spindle-shaped osteoblasts (Figs. 1F and F′), demonstrating
that FGFR1 is expressed in different stages of osteoblast
maturation.
Conditional inactivation of Fgfr1 in osteo-chondro-progenitor
cell lineages
To address the role of FGFR1 in the chondrocyte and
osteoblast lineages, a floxed allele of Fgfr1 (Trokovic et al.,
2003) was targeted with a proα1(II) collagen-Cre (Col2-Cre)
transgene (Ovchinnikov et al., 2000). Type II collagen is an
early marker of the mesenchymal condensation and, later in
development, a specific marker for the chondrocyte lineage.
Mating of Col2-Cre mice with ROSA26 reporter mice (R26R)
(Soriano, 1999) activated β-galactosidase (β-gal) expression in
both the chondrocyte and osteoblast lineages, but not in
osteoclasts or bone marrow stroma (Fig. 2A, and data not
shown) (Ovchinnikov et al., 2000).
To inactivate Fgfr1 in the osteo-chondrocyte lineage,
Fgfr1Δ/+,Col2-Cre/+ mice were mated to Fgfr1flox/flox mice.
Conditional knockout mice (Fgfr1Col2-cko), born with a normal
Mendelian frequency, were indistinguishable from wild-type
littermates. Skeletal preparations of P0 mice revealed a rounded
cranium but an otherwise normal appearing skeleton with no
delay in the formation of ossification centers. The efficiency of
Col2-Cre mediated Fgfr1 gene deletion was analyzed by RNA
in situ hybridization. Histological sections of the femur of
Fgfr1Col2-cko embryos showed loss of Fgfr1 expression in
hypertrophic chondrocytes and trace levels of expression in
trabecular bone and in the periosteum (Figs. 2B and C),
suggesting nearly complete inactivation of the Fgfr1 gene in
skeletal lineages.
Defects in growth plate development in Fgfr1Col2-cko mice
To examine the growth plate of Fgfr1Col2-cko mice,
histological sections were prepared from E16.5-18.5 limbs. At
E16.4, femur and tibia sections showed a∼60% increase (femur
58%, P = 0.0001, n = 6; tibia 68%, P = 0.0003, n = 5) in the
height of the hypertrophic chondrocyte zone in Fgfr1Col2-cko
mice compared to littermate controls (Figs. 2D and E). No
significant change was observed in the proliferating or pre-
hypertrophic regions. The increased size of the hypertrophic
zone seen in Fgfr1Col2-cko embryos could result from increased
differentiation, increased cell size or decreased loss of cells at
the chondro-osseous junction. Histological sections suggested
that cell size was not affected by loss of FGFR1 signaling. To
examine chondrocyte differentiation, the expression of the
parathyroid hormone receptor (Pth1r) and Indian hedgehog
(Ihh) was examined by in situ hybridization. Both of these genes
are expressed in pre-hypertrophic chondrocytes and define the
pool of cells that is committed to hypertrophy. Similar levels of
expression of Pth1r and Ihh were observed in Fgfr1Col2-cko and
control growth plates at E16.5 and at E18.5, suggesting that the
rate of chondrocyte differentiation was not significantly affected
Fig. 1. Identification of FGFR1-expressing osteoblast populations in developing endochondral bone. (A–C) Neonatal (P0) proximal femur histology stained with
hematoxylin and eosin. Proximal (B) and distal (C) trabecular regions are shown at high magnification to identify cubiodal (arrowhead in panel B) and spindle-
shaped (arrow in C) osteoblasts lining bone trabeculae. (D–F′) Immunohistochemical identification of osteopontin, β-catenin and FGFR1 in proximal (D–F) and
distal (D′–F′) trabecular regions. Osteopontin immunohistochemistry (D and D′) and β-catenin immunohistochemistry (E and E′) identifying cuboidal osteoblasts
(arrowhead) in proximal trabecular regions (D, E) and spindle-shaped osteoblasts (arrow) lining bone trabeculae in distal trabecular regions (D′, E′). FGFR1
immunohistochemistry also identifies cuboidal cells in proximal trabecular regions (F) and spindle shaped cells lining trabeculae in distal trabecular regions (F′). A,
10× objective; B–F′, 40× objective.
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assessed by BrdU immunohistochemistry, showed no signifi-
cant difference between Fgfr1Col2-cko and control tibia (Figs. 2J
and K) or femur (Supplementary Figs. 1A and B) growth plates
at E18.5.
Delayed terminal differentiation of hypertrophic chondro-
cytes could also account for an increased hypertrophic
chondrocyte zone. Type X collagen (ColX), a specific marker
of the hypertrophic chondrocyte, was expressed at a similar
intensity in both Fgfr1Col2-cko and control growth plates at
E16.5. However, in Fgfr1Col2-cko growth plates, the area of
expression was broader and ColX-positive cells were found
ectopically located in the trabecular region (Figs. 3A and B).
This suggested that the degradation of hypertrophic chondro-
cytes was delayed. Osteopontin (Opn) is expressed in distal
hypertrophic zone chondrocytes and in osteoblasts (Lian et al.,
1993). Opn expression at the chondro-osseous junction was
significantly reduced in Fgfr1Col2-cko embryos at E18.5
(Figs. 3C and D). This suggested that maturation of hypertro-phic chondrocytes and/or trabecular osteoblasts was delayed.
The frequency of apoptotic cells (TUNEL labeling) in the distal
hypertrophic regions was low at this stage of development but
appeared similar in control and Fgfr1Col2-cko growth plates (data
not shown).
Vascular invasion of the hypertrophic zone is required for the
influx of both osteoblasts and osteoclasts. Osteoclasts are
necessary for cartilage matrix degradation, an initial step in bone
marrow cavity formation. MMP9 andMMP13 are proteases that
are required for this process (Ortega et al., 2004; Stickens et al.,
2004; Vu et al., 1998). Mmp9 is highly expressed in terminal
hypertrophic chondrocytes, monocytes and in osteoclast/
chondroclasts. Mmp13 is expressed by terminal hypertrophic
chondrocytes and osteoblasts. Mice lacking either Mmp9 or
Mmp13 develop an expanded hypertrophic zone andMmp9 and
Mmp13 synergize with each other in this process (Stickens et
al., 2004). In Fgfr1Col2-cko embryos at E18.5, in situ hybridi-
zation analysis showed that Mmp9 expression was reduced at
the chondro-osseous junction (Figs. 3E and F). This was
Fig. 2. Col2-Cre-mediated inactivation of Fgfr1. (A) Histological section of the distal femur from a P10 Col2-Cre,R26R mouse showing X-gal staining in both
chondrocytes and osteoblasts. (B, C) Expression of Fgfr1 at E16.5 in the femur from a control (B) and an Fgfr1Col2-cko (C) embryo showing loss of Fgfr1 expression in
hypertrophic chondrocytes, and reduced expression in perichondrial and trabeculae tissue. Note that Fgfr1 expression is normally excluded from proliferating
chondrocytes. (D, E) Hematoxylin and eosin-stained sections of femur from control (D) and Fgfr1Col2-cko (E) embryos at E16.5 showing an expanded HC zone in the
absence of Fgfr1. (F–I) Expression analysis of Ihh (F, G) and Pth1r (H, I) in the femur at E16.5. No significant difference in expression in control (F, H) and
Fgfr1Col2-cko (G, I) embryos was observed. (J, K) BrdU labeling of the proximal tibia at E18.5 showing no significant difference in proliferation in control (J) and
Fgfr1Col2-cko (K) embryos. A–C, J, K, 20× objective; D–I, 10× objective. r, reserve chondrocyte zone; p, proliferating chondrocyte zone; h, hypertrophic
chondrocyte zone; b, trabecular bone.
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acid phosphatase) mRNA (Figs. 3G and H) and a 49% decrease
in the number of cells positive for TRAP enzymatic activity in
the femur diaphyses of E16.5 Fgfr1Col2-cko embryos (n = 3,
P = 0.006) (Supplementary Figs. 1C and D). The level of
expression of Mmp13 was similar in control and Fgfr1Col2-cko
embryos (data not shown). By postnatal day 14 (P14), the length
of the hypertrophic chondrocyte zone returned to normal in
Fgfr1Col2-cko mice (data not shown). This transient expansion of
the hypertrophic zone is similar towhat hasbeen seen inMmp9−/−
andMmp13−/−mice (Stickens et al., 2004).
Fgfr1 regulates osteoblast function but not cell fate
specification
Cbfa1/Runx2 is a transcription factor required for chon-
drogenesis and osteogenesis. Cbfa1 is expressed in osteopro-genitor cells, prior to the earliest stages of ossification, in
proliferating chondrocytes and in osteoblasts (Otto et al.,
1997; Yoshida et al., 2002). Histological analysis of E16.5
Fgfr1Col2-cko femurs showed normal levels of Cbfa1 expres-
sion in chondrocytes and in periosteal and trabecular regions,
indicating normal specification of the chondrocyte and
osteoblast lineage (Figs. 3I and J). Interestingly, expression
of Type I collagen, a marker of differentiating osteoblasts, was
reduced in Fgfr1Col2-cko embryos (Figs. 3K and L), suggesting
a delay in osteoblast differentiation or an anabolic deficit in
the osteoblast. Osteocalcin (Oc), a marker of differentiated
osteoblasts, was expressed at very low levels in both control
and Fgfr1Col2-cko embryos at this stage, and no difference in
expression could be detected (data not shown). However, by
postnatal day 14, Oc expression was reduced in the secondary
ossification center of Fgfr1Col2-cko mouse femurs (Supplemen-
tary Figs. 1E and F).
Fig. 3. Development of the distal chondro-osseous junction of the femur of Fgfr1Col2-cko mice at E16.5. (A, B) Type X collagen expression showing an expanded
hypertrophic chondrocyte zone and type X collagen-expressing cells in the trabecular region CKO tissue (B). (C, D) Osteopontin expression is reduced in Fgfr1Col2-cko
femurs (D) indicating delayed osteoblast differentiation. Mmp9 (E, F) and Trap (G, H) in situ hybridization showing reduced expression of both markers at the
chondro-osseous junction in Fgfr1Col2-cko femurs (F, H) compared to controls (E, G). (I–L) Expression of Cbfa1 (I, J) and type I collagen (K, L), showing similar levels
of expression of Cbfa1 but reduced levels of expression of type 1 collagen in Fgfr1Col2-cko femurs (J, L) compared to controls (I, K). (A–L) 10× objective. p,
proliferating chondrocyte zone; h, hypertrophic chondrocyte zone; b, trabecular bone.
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compartment
To assess the function of Fgfr1 in differentiated osteoblasts
that express type I collagen, an α1(I)-collagen-Cre (Col1-Cre)
transgenic line (Dacquin et al., 2002) was used to selectively
inactivate the floxed allele of Fgfr1. ColI-Cre transgenic mice,
when crossed with a β-galactosidase reporter line (R26R),
showed β-gal activity in the periosteum and trabecular region,
indicating that Cre activity was restricted to differentiated
osteoblasts (Fig. 4A). Specificity of the Fgfr1 gene deletion was
demonstrated by genomic PCR, which showed the presence of a
deleted Fgfr1 allele (Fgfr1Δ) in bone but not kidney tissue from
Fgfr1flox/flox,ColI-Cre/+ mice (Fig. 4B). Immunohistochemical
analysis of FGFR1 expression in trabecular bone also showed a
reduction in FGFR1 staining intensity in Fgfr1flox/Δ,ColI-Cre/+
conditional knockout (Fgfr1ColI-cko) tissue compared to control
tissue (Figs. 4C and D). To further examine Fgfr1 gene
inactivation in osteoblasts, cultured long-bone-derived osteo-
blasts were allowed to differentiate in vitro and were then
analyzed for the Fgfr1 gene deletion. The Fgfr1Δ allele wasdetected in osteoblast cultures derived from Fgfr1ColI-cko mice
but not in osteoclast cultures derived from the same mice
(Fig. 4E). RT-PCR analysis showed that mRNA containing the
Cre-induced deletion was expressed in osteoblast cultures
derived from Fgfr1ColI-ckomice but not from control Fgfr1flox/flox
mice (Fig. 4F). Interestingly, higher levels of Fgfr1Δ were
detected in osteoblasts that were induced to differentiate with
dexamethasone, consistent with expression of Col1 in more
differentiated osteoblasts.
Increased trabecular bone volume in Fgfr1ColI-cko neonatal
mice
Histological sections, prepared from the femur and tibia of
neonatal mice, showed increased trabecular bone volume and a
decreased marrow space in Fgfr1ColI-cko embryos (Figs. 5A and
B). Morphometric analysis of histological sections showed a
54% increase in the trabecular bone volume/total volume ratio
in neonatal Fgfr1ColI-cko mice (Fig. 5C). Examination of
trabecular architecture showed decreased cartilage matrix and
increased osteoid in Fgfr1ColI-cko embryos. This suggested an
Fig. 4. Col1-Cre-mediated inactivation of Fgfr1. (A) Histological section of the distal femur from a P7 ColI-Cre, R26R animal showing X-gal staining in osteoblasts
lining trabecular bone. (B) Genomic PCR analysis showing Cre-mediated deletion of the Fgfr1 floxed allele in two month-old Fgfr1ColI-cko and control mice. PCR
amplification of the deleted allele of Fgfr1 (Δ) was detected in bone but not kidney from Fgfr1ColI-ckomice (lanes 2 and 4). The Fgfr1 (Δ) allele was not detected in the
absence of Cre (lanes 1 and 3). (C, D) Immunohistochemical detection of FGFR1 in P0 Fgfr1flox/flox (C) and Fgfr1ColI-cko (D) femurs showing decreased expression in
Fgfr1ColI-cko tissue. Dotted lines outline trabecular bone (b). (E) Genomic PCR analysis of primary osteoclasts (OC, lanes 1 and 2) and osteoblasts (OB, lanes 3 and 4)
showing Cre-mediated deletion of the Fgfr1 floxed allele only in osteoblast cultures from Fgfr1ColI-cko mice (lane 4). (F) RT-PCR analysis showing expression of the
deleted Fgfr1 allele (Δ) in Fgfr1ColI-cko-derived osteoblasts (cko) but not in control (F/F) osteoblasts. Dexamethasone (Dex)-treated Fgfr1ColI-cko osteoblasts increased
the level of Fgfr1Δ expression. Gapdh expression was used as a control for cDNA synthesis and PCR amplification. A, C and D, 10× objective.
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deposition of bone matrix in mice with Fgfr1-deficient
osteoblasts. Consistent with this, von Kossa staining showed
increased mineralization in the trabecular region of Fgfr1ColI-cko
mice compared to control mice (Figs. 5E and F). Morphometric
analysis of Fgfr1ColI-cko neonatal limbs showed a 52% reduction
in the number of cuboidal-shaped osteoblasts in the trabecular
region (Fig. 5D). At high magnification, these osteoblasts
appeared to have an increased cytoplasmic area compared to
wild-type osteoblasts (data not shown).The observed increased trabecular bone volume could result
from a combination of either increased deposition of bone
matrix or decreased degradation and remodeling of bone.
Because osteoclasts are essential for the bone remodeling
process and are required to maintain the bone marrow cavity, we
examined osteoclast number and morphology in bones from
neonatal Fgfr1ColI-cko embryos by staining for tartrate-resistant
acid phosphatase (TRAP) activity. The number of TRAP-
positive osteoclasts in Fgfr1ColI-cko embryos was similar to that
in wild-type embryos, suggesting normal numbers of osteoclast
Fig. 5. Increased trabecular bone volume and enhanced osteoblast ossification in Fgfr1ColI-cko mice. (A, B) Hematoxylin and eosin-stained sections of the distal femur at P0 mice showing increased trabecular bone in
Fgfr1ColI-cko (B) compared to control (A) mice. (C, D) Morphometric analysis of P0 mouse femur trabecular bone showing increased bone volume (BV) to total volume (TV) ratio and decreased number of cuboidal
osteoblasts in Fgfr1ColI-cko (CKO) compared to control (F/F) mice. *P < 0.05, **P = 0.004. (E, F) Mineralization of the distal femur at P0 detected by von Kossa staining, showing increased mineralization in the
trabecular region in Fgfr1ColI-cko (F) compared to control (E) mice. (G, H) TRAP stain of distal femur sections from control mice showing osteoclasts spread over bone trabeculae in control bone (G, G′) but appearing
more rounded and less adherent in Fgfr1ColI-cko bone (H, H′). (I–L) Detection of maturing osteoblasts with X-gal staining of P0 control (Col1-Cre,R26R) and Fgfr1Col1-cko,R26R femur. (I, J) Whole-mount X-gal staining
analysis showing intense staining in the trabeculae and cortical region in Fgfr1ColI-cko femur. (K, L) Histological sections showing increased numbers of X-gal-positive osteoblasts in Fgfr1ColI-cko (L) compared to control
(K) femurs. A, B, E–H, 10× objective; K, L, G′, H′, 20× objective. h, hypertrophic chondrocyte zone; b, trabecular bone; p, periosteum.
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Fig. 6. Growth and differentiation of osteoprogenitor cells in vitro. (A–E) Osteoprogenitor cell cultures derived from control and Fgfr1Col2-cko long bones. (A) Cell
proliferation, assessed by 3H-thymidine incorporation, is increased in Fgfr1Col2-cko cells compared to control cells (n = 3, * P = 0.02). (B) Alkaline phosphatase activity
is decreased in Fgfr1Col2-cko cells compared to control cells (n = 3, ** P < 0.001). (C–E) Alizarin red staining of osteoprogenitor cells maintained in mineralization
medium for 3 weeks showing fewer mineralized nodules in Fgfr1Col2-cko cultures (D) compared to control cultures (C). (E) Quantification of the mineral deposition in
Fgfr1Col2-cko and control cultures (n = 3, * P = 0.01). (F–H) Alizarin red staining of osteoprogenitor cells derived from control and Fgfr1Col1-cko long bones maintained
in mineralization medium for 3 weeks showing increased numbers of mineralized nodules in Fgfr1Col1-cko cultures (F) compared to control cultures (G). (H)
Quantification of the mineral deposition in Fgfr1Col1-cko and control cultures (n = 3, * P = 0.01). (I) Quantitative RT-PCR analysis of osteoblast cultures maintained in
mineralization medium for 1 week showing decreased expression of Fgfr1 (n = 3, ** P < 0.0001) and Col1 (n = 3, * P < 0.01) in Fgfr1Col2-cko cultures (solid bars)
compared to control cultures (open bars). (J) Quantitative RT-PCR analysis of osteoblast cultures maintained in mineralization medium for 2 weeks showing increased
expression of Fgfr3 in Fgfr1Col1-cko cultures (solid bar) compared to control cultures (open bar) (n = 4, ** P < 0.008).
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embryos, TRAP-positive cells were smaller and more rounded,
whereas in control embryos, these cells were larger, flattened
and spread over bone spicules (Figs. 5G′ and H′). Given that the
Col1-Cre transgene showed no recombinase activity in culturedosteoclasts (Fig. 4E), the observed morphologic defect in
osteoclast differentiation is likely to be secondary to FGFR1-
dependent activities in osteoblasts.
To assess the extent of osteoblast maturation in control and
Fgfr1ColI-cko embryos, we introduced the R26R reporter allele
325A.L. Jacob et al. / Developmental Biology 296 (2006) 315–328into this genetic background. β-Gal staining acts as a marker to
identify differentiated osteoblasts that have expressed Col1-Cre.
In Col1-Cre,R26R mice, β-gal staining can be detected by
postnatal day 5 (P5) in trabecular zone osteoblasts (Dacquin
et al., 2002). Interestingly, whole-mount and histological
sections of P0 femurs from Fgfr1ColI-cko, R26R embryos
showed an increase in the intensity of β-gal staining compared
to that of femurs from Col1-Cre,Fgfr1flox/+,R26R control
embryos (Figs. 5I–L). Because Col1-Cre should be inactivat-
ing, Fgfr1and activating R26R simultaneously only in differ-
entiated osteoblasts, this observation suggests that differentiated
osteoblasts lacking FGFR1 may enhance maturation of
neighboring immature osteoblasts, thus increasing the number
of cells expressing Cre recombinase. To further examine the
affects of loss of FGFR1 on osteoblast maturation, we examined
osteoblast maturation in vitro.
Osteoblast differentiation, in vitro
To examine the effect of FGFR1 on the ability of osteoblasts
to differentiate in vitro, osteoblast cultures were prepared from
the femur and tibia of 1.5- to 2-month-old wild-type and Fgfr1
conditional knockout mice. Osteoblast cultures prepared from
Fgfr1Col2-cko mice showed a 39% increase in the rate of
proliferation compared to cultures prepared from control mice
(Fig. 6A). Furthermore, alkaline phosphatase activity was
significantly lower in Fgfr1Col2-cko-derived cultures (Fig. 6B).
These data suggest that FGFR1 signaling normally acts to
inhibit proliferation and enhance commitment to the osteoblast
lineage in osteo-chondro-progenitor cells. To assess the ability
of FGFR1-deficient osteo-progenitor cells to differentiate and
mineralize, cultures were treated with medium containing β-
glycerophosphate and ascorbic acid. After three weeks in
mineralization medium, mineralized bone nodules were iden-
tified by alizarin red staining. Consistent with delayed
osteoblast maturation, Alizarin red binding was decreased by
3.3-fold in Fgfr1Col2-cko cultures compared to control cultures
(Figs. 6C–E).
In contrast to cultures prepared from Fgfr1Col2-cko mice,
cultures prepared from the femur and tibia of 1.5- to 2-month-
old Fgfr1Col1-cko mice showed similar levels of alkaline
phosphatase activity and no change in the rates of proliferation
after one week in culture. These data suggest that differentiation
of osteo-chondro-progenitor cells were not affected by Col1-
Cre, consistent with Cre expression only in differentiated
osteoblasts. However, when Fgfr1Col1-cko cultures were placed
in mineralization medium for three weeks, alizarin red stainingFig. 7. Skeletal maturation. (A, B) Hematoxylin and eosin-stained sections from co
irregular formation of the trabecular region, ectopic islands of hypertrophic chondrocy
in Fgfr1ColI-cko tissue. (C–I) Increased bone formation in adult mice lacking Fgfr1.
Fgfr1ColI-cko (D) mouse. Increased trabecular bone formation and trabeculae-like struc
analysis of femur trabecular bone showing a 3 ± 0.5-fold increase in the bone volume
mice (n = 4, **P < 0.001). Histological sections of the distal femur of a five-mont
formation. (H) Morphometric analysis of the femur diaphysis showing a 40% increase
(F/F) mice (n = 3, *P = 0.01). (I) DEXA analysis showing a 14% increase in bone mi
*P = 0.02). A and B, 10×; C and D, 2.5×; F and G, 4×.showed significantly more intense staining than control cells
(2.3-fold increase in alizarin red binding) (Figs. 6F–H). These
data indicate that once osteoblasts are induced to mature,
inactivation of Fgfr1 can further enhance their differentiation.
Osteoblast cultures lacking Fgfr2 or Fgfr3 show decreased
mineralization (Valverde-Franco et al., 2004 and data not
shown). Fgfr3−/− cultures also showed increased expression of
Fgfr1 (Valverde-Franco et al., 2004). Another mechanism by
which FGFR1 signaling could regulate osteoblast maturation
could be by regulating the expression of Fgfr2 and Fgfr3. We
therefore examined the expression of Fgfr2 and Fgfr3 in
Fgfr1ColI-cko osteoblasts cultured under ossifying conditions. In
cultures prepared from Fgfr1Col2-cko mice, no significant change
in the levels of expression of Fgfr2 and Fgfr3, but a significant
decrease in the level of Col1 was observed (Fig. 6I). In cultures
prepared from Fgfr1Col1-cko mice, an increased level of
expression of Fgfr3 was observed (Fig. 6J). This is consistent
with FGFR3 acting in differentiated osteoblasts to stimulate
mineralization (Valverde-Franco et al., 2004).
Bone pathology during skeletal maturation
Histological analysis of the growth plate of P10 to P15
Fgfr1Col1-cko animals showed a partial resolution of the
trabecular bone overgrowth phenotype seen at earlier ages.
However, the trabecular region remained disorganized with
persistent islands of hypertrophic chondrocytes trapped within
trabecular bone and vascular sinuses encroaching on the
chondro-osseous junction (Figs. 7A and B). By P10, both
control and Fgfr1Col1-cko bones showed normalized osteoclast
morphology, with multinucleated osteoclasts attached and
spread out over trabeculae (data not shown). Examination of
histological sections of femur and tibia of eight-month-old
Fgfr1Col1-cko mice showed increased trabecular bone com-
pared to age matched control mice (Figs. 7C and D).
Morphometric analysis of the femurs revealed a 3 ± 0.5-fold
increase in the trabeculae bone volume compared to control
mice (Fig. 7E).
Histological analysis of femur and tibia sections of six month
and older Fgfr1Col2-cko mice showed increased cortical bone
thickness compared to age-matched controls (Figs. 7F–H);
however, the trabecular regions appeared normal. Radiological
examination of Fgfr1Col2-cko mice also showed increased
cortical thickness of the femur and tibia (not shown). Consistent
with increased cortical thickness, whole body bone mineral
density (DEXA) was increased by 14% in female Fgfr1Col2-cko
mice compared to age matched controls (Fig. 7I).ntrol (A) and Fgfr1ColI-cko (B) distal femurs at postnatal day 10 (P10) showing
tes and the presence of vascular sinuses adjacent to the chondro-osseous junction
Histological sections of the distal femur of an eight-month-old control (C) and
tures lining the cortical bone are evident in Fgfr1ColI-cko tissue. (E) Morphometric
(BV) to total volume (TV) ratio in Fgfr1ColI-cko (CKO) compared to control (F/F)
h-old control (F) and Fgfr1Col2-cko (G) mouse showing increased cortical bone
in the diaphyseal bone volume (BV) in Fgfr1Col2-cko (CKO) compared to control
neral density of Fgfr1Col2-cko compared to control mice (n = 5, WT; n = 6, CKO,
Fig. 8. Model for FGFR1 regulation of osteoblast maturation. Inactivation of
Fgfr1 at different stages of osteoblast development was achieved by using two
different Cre-expressing transgenic lines. Col2-Cre inactivates Fgfr1 before
commitment to the osteoblast lineage whereas Col1-Cre inactivates Fgfr1 after
commitment to the osteoblast lineage (dashed lines). (A) FGFR1 functions at
early stages of osteoprogenitor development to inhibit cell proliferation and
promote differentiation. (B) FGFR1 also functions in committed osteoblasts to
prevent further differentiation and mineralization. AP, alkaline phosphatase;
Col1, type I collagen.
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Mutations in FGFR1 that cause Pfeiffer syndrome, Jackson–
Weiss syndrome and osteoglophonic dysplasia in humans
(Roscioli et al., 2000; Schell et al., 1995; White et al., 2005)
provide genetic evidence for a role for FGFR1 in skeletal
development. To define the function of FGFR1 in chondrocytes
and in early and late stages of osteoblast development, we have
conditionally inactivated a floxed allele of Fgfr1 in osteo-
chondro-progenitor cells using Col2-Cre and in differentiated
osteoblasts using Col1-Cre. Fgfr1Col2-cko mice developed
defects in both chondrocytes and osteoblasts, whereas the
phenotype of Fgfr1Col1-cko mice was restricted to osteoblasts.
Although Fgfr1Col2-cko mice developed an expanded hyper-
trophic chondrocyte zone, the precise role for FGFR1 signaling
in the hypertrophic chondrocyte cannot be determined from
these experiments because Fgfr1 is expressed and inactivated in
both chondrocytes and cells within the perichondrium and
chondro-osseous junction. Nevertheless, the experiments
shown here suggest that loss of FGFR1 signaling primarily
affects hypertrophic chondrocytes by acting on the chondro-
osseous junction to limit mechanisms that degrade hypertrophic
chondrocytes. For example, Fgfr1Col2-ckomice had decreased
expression of MMP9 and decreased numbers of osteoclasts at
the chondro-osseous junction, which could delay the degrada-
tion of hypertrophic chondrocytes (Ortega et al., 2004; Vu et al.,
1998). Additionally, maturation of hypertrophic chondrocytes
may also be delayed, as indicated by reduced expression of
osteopontin. Interestingly, in mice in which Fgfr2 was inacti-
vated in a similar pattern with Dermo1-Cre, the hypertrophic
chondrocyte zone was decreased at later stages of development
(P7 versus E16.5), and osteoclast numbers at the chondro-
osseous junction were increased (Eswarakumar et al., 2002; Yu
et al., 2003). Thus, although acting most potently at different
stages of skeletal development, FGFR1 and FGFR2 appear to
have opposite affects on distal growth plate development. This
could be due to differential activation of FGFR1 and FGFR2 by
FGF ligands, differences in the strength or downstream
components of the FGFR signals, or expression of FGFR1
and FGFR2 at different stages of osteoblast and chondrocyte
development.
Fgfr regulation of osteoblast proliferation and differentiation
Inactivation of FGFR1 in immature osteoblasts (Fgfr1Col2-cko)
did not affect formation of osteoprogenitor cells, as indicated by
normal levels of expression ofCbfa1, but did cause a delay in the
maturation of osteoblasts, as shown by reduced expression of
type 1 collagen and osteopontin. Consistent with this, osteopro-
genitor cell cultures derived from cortical bone of Fgfr1Col2-cko
mice showed increased rates of proliferation and decreased
differentiation (decreased alkaline phosphatase expression and
delayed mineralization). These data suggest that FGFR1
signaling in the osteoprogenitor cell normally acts to suppress
proliferation and stimulate differentiation (Fig. 8A). In contrast,
when Fgfr1ColI-cko osteoblasts were cultured under ossifying
conditions, they showed accelerated differentiation, demonstrat-ing that in differentiated osteoblasts, FGFR1 functions to
suppress differentiation (Fig. 8B). Thus, FGFR1 signaling has
stage-specific effects on osteoblast maturation.
Regulation of osteoclast activation by osteoblast-FGFR1
signaling
Osteoclasts must spread out and attach to bone matrix to
carry out their normal catabolic function (Teitelbaum, 2000).
The observation that osteoclasts are smaller and not spread out
over bone trabeculae in neonatal Fgfr1ColI-cko mice correlated
with the observed increase in trabecular bone volume. This
phenotype supports the hypothesis that Fgfr1-deficient osteo-
blasts cannot maintain normal osteoclast activity during this
developmental period. We therefore hypothesized that FGFR1
signaling through the osteoblast must be involved in the
regulation of osteoclastogenic cytokine production. Consistent
with this, preliminary data shows that Fgfr1ColI-cko osteoblast
cultures express less RANKL (receptor activator of NFκβ
ligand) and are not able to support osteoclastogenesis in in vitro
co-culture. Further experiments will explore the stage-specific
role of FGFR signaling in undifferentiated and differentiated
osteoblasts' ability to produce RANKL and other cytokines that
regulate osteoclast activity.
FGF signaling regulates bone growth
Increased anabolic activity in Fgfr1ColI-cko osteoblasts was
supported by the observation of increased numbers of β-gal-
positive osteoblasts in Fgfr1Col1-cko;R26R embryos compared to
ColI-Cre;R26R embryos. In contrast to mice lacking Fgfr1,
mice lacking Fgfr2 or Fgfr3 became osteopenic as adults
(Eswarakumar et al., 2002; Valverde-Franco et al., 2004; Yu
et al., 2003). Thus, signaling through FGFR2 and FGFR3
acts to enhance bone formation. Consistent with this activity,
osteoblast cultures derived from Fgfr2Col1-cko mice or
Fgfr3−/− mice showed decreased mineralization when com-
pared to control cultures (Valverde-Franco et al., 2004 and
data not shown). The accelerated mineralization of Fgfr1ColI-
327A.L. Jacob et al. / Developmental Biology 296 (2006) 315–328cko osteoblasts in culture may be further enhanced by
increased expression and activity of Fgfr3.
The FGF ligands that signal to FGFR1 in osteoblasts are not
known; however, three FGFs (FGFs 2, 9 and 18) are likely
candidates for this role. FGF9 and FGF18 are expressed in the
perichondrium/periosteum, and mice lacking these FGFs show
delayed ossification during mid-gestation skeletogenesis
(Colvin et al., 1999; Liu et al., 2002; Ohbayashi et al., 2002)
(I. Hung, DMO, unpublished data). FGF2 is expressed in
periosteal cells and osteoblasts (Hurley et al., 1999; Sabbieti
et al., 1999) and adult Fgf2−/− mice showed a loss of trabecular
bone volume; however, no skeletal dysmorphology was
reported in neonatal Fgf2−/− mice (Montero et al., 2000).
These observations suggest that FGFs 2, 9 and 18 may act alone
or redundantly to regulate osteoblast activity and physiology
and that FGFs 9 and 18 may constitute the predominant signals
during embryonic development, whereas FGF2 may be more
important during postnatal stages. Consistent with a role for
FGF2 in more differentiated osteoblasts, bone marrow stromal
cultures from Fgf2−/− mice showed a significantly decreased
ability to mineralize in vitro (Montero et al., 2000). The
phenotypic similarities in Fgf2−/− mice and Fgfr3−/− mice
suggest that FGF2 may signal through FGFR3 in osteoblasts to
enhance mineralization.
The increased formation of bone at early ages and the
increased number and rate of mineralization of differentiated
osteoblasts could lead to the observed increase in bone volume
observed in older mice. Furthermore, because in older mice
chondrogenesis is not an active process and osteoblasts have
progressed towards maturity, similarities between adult
Fgfr1ColI-cko and Fgfr1Col2-cko mice suggest that the predom-
inant role for FGFR1 signaling in mature bone is to decrease
anabolic activity and slow terminal differentiation (mineraliza-
tion) of osteoblasts (Fig. 8B). A component of this mechanism
may be through suppression of FGFR3 expression.
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